We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
Sonova, headquartered in Stäfa, Switzerland, is a leading provider of innovative h...
Sonova, headquartered in Stäfa, Switzerland, is...
CPSI is a leading provider of healthcare solutions and services for community hosp...
CPSI is a leading provider of healthcare soluti...
Intrommune Therapeutics is a New York City-based biopharmaceutical company develop...
Intrommune Therapeutics is a New York City-base...
DarĂŠ Bioscience is a clinical-stage biopharmaceutical company committed to the ad...
DarĂŠ Bioscience is a clinical-stage biopharmac...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Join the National Investor Network and get the latest information with your interests in mind.